BioSpace News Archive

Schrödinger announced new preclinical data on SGR-1505, its investigational MALT1 inhibitor, and SGR-2921, its investigational CDC7 inhibitor, in a poster session at the American Society of Hematology 65th Annual Meeting taking place virtually and in San Diego, California.

ImmunoGen Inc. announced new safety and efficacy findings from the newly diagnosed cohorts of the Phase 1b/2 study of pivekimab sunirine in combination with azacitidine and venetoclax, in patients with ND acute myeloid leukemia.

Adicet Bio, Inc. announced that an abstract outlining PK and PD profiling data from the Company’s ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory aggressive B-cell NHL was made available as part of the 65th ASH Annual Meeting, being held December 9-12, 2023 in San Diego, California.

Regeneron Pharmaceuticals, Inc. announced new and updated data for odronextamab in patients with relapsed/refractory diffuse large B-cell lymphoma.

Be Biopharma, Inc., a company pioneering the discovery and development of Engineered B Cell Medicines, announced results from a new preclinical study demonstrating that the company’s novel engineered BCM, BE-101, produces active and sustained levels of Factor IX for the treatment of hemophilia B. These data were shared during an oral presentation at the 65th annual meeting of the American Society of Hematology taking place in San Diego, California.

The Phase 3 trial investigating Sarclisa® in combination with carfilzomib, lenalidomide and dexamethasone showed a statistically significant improvement in the rate of minimal residual disease negativity, compared with KRd alone, after autologous stem cell transplant consolidation in transplant-eligible patients with newly diagnosed multiple myeloma.

InnoCare Pharma, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that the latest data from InnoCare’s oncology studies were presented at the 65th American Society of Hematology Annual Meeting.

Seagen Inc. announced that clinically meaningful progression-free survival, a secondary endpoint, was observed in a Phase 2 study evaluating the antibody-drug conjugate ADCETRIS® in combination with the PD-1 inhibitor nivolumab and standard chemotherapy agents doxorubicin and dacarbazine as first-line treatment for early and advanced stage classical Hodgkin lymphoma.

Genentech, a member of the Roche Group, announced that new data from its CD20xCD3 T-cell engaging bispecific antibody program, including eight oral presentations, were presented at the 65th American Society of Hematology Annual Meeting & Exposition, December 9-12, 2023.

Nona Biosciences and Evive Biotech announced a collaboration agreement on antibody discovery based on the Harbour Mice® antibody technology platform of Nona Biosciences.